Contract 36F79724D0115
Revance Therapeutics, Inc. · Department Of Veterans Affairs · April 22, 2024
Revance Therapeutics, Inc. was awarded a federal contract by Department Of Veterans Affairs on April 22, 2024 for an undisclosed amount of work in pharmaceutical preparation manufacturing. It was awarded under full and open competition. The contract has been modified 4 times since the base award It uses firm fixed-price contract pricing. The most recent modification was on December 11, 2025. If all options are exercised, the contract could reach $225,000.
Contract details
- PIID
- 36F79724D0115
- Award type
- —
- Pricing
- Fixed Price With Economic Price Adjustment
- Set-aside
- No Set Aside Used.
- Competition
- Full And Open Competition
- NAICS
- 325412 · Pharmaceutical Preparation Manufacturing
- Product / service
- Drugs And Biologicals
- First action
- April 22, 2024
- Latest action
- December 11, 2025
Description
2026 PUBLIC LAW 102-585 PRICING UPDATE
Modification timeline
-
December 11, 2025Mod P00004$0
-
July 31, 2025Mod P00003UPDATE POC & SIGNATURE AUTHORITY$0
-
December 2, 2024Mod P000022025 PUBLIC LAW UPDATES$0
-
June 19, 2024Mod P0000165IB / ADMINISTRATIVE CHANGE: UPDATE: ALTERNATE POC & IFF SALES POC$0
-
April 22, 2024Base award65 I B, DRUGS, PHARMACEUTICALS, & HEMATOLOGY RELATED PRODUCTS, FSS CONTRACT AWARD$0
Similar contracts
| Recipient | Agency | Date | Obligated |
|---|---|---|---|
| Petnet Solutions, Inc. | Department Of Veterans Affairs | April 1, 2026 | $387.4K |
| Eli Lilly And Company | Department Of Veterans Affairs | April 1, 2026 | $0 |
| Exelan Pharmaceuticals Inc | Department Of Veterans Affairs | April 1, 2026 | $0 |
| Cardinal Health 414, Llc | Department Of Veterans Affairs | April 1, 2026 | $122.9K |
| Guardian Pharmacy Of Indianapolis Nuclear, Llc | Department Of Veterans Affairs | April 1, 2026 | $0 |
| Jubilant Draximage Inc | Department Of Veterans Affairs | April 1, 2026 | $0 |
Top contractors in NAICS 325412
Lifetime obligated dollars across all federal contracts in this NAICS code.
| # | Contractor | Contracts | Obligated |
|---|---|---|---|
| 1 | Mckesson Corporation | 53,729 | $99.76B |
| 2 | Pfizer Inc | 4,613 | $28.68B |
| 3 | Merck Sharp & Dohme Llc | 391 | $21.58B |
| 4 | Modernatx, Inc. | 3 | $8.20B |
| 5 | Sanofi Vaccines Us Inc. | 5,248 | $7.76B |
| 6 | Glaxosmithkline, Llc | 1,418 | $7.22B |
| 7 | Merck Sharp & Dohme Corp. | 349 | $5.33B |
| 8 | Pfizer Inc. | 3,842 | $4.83B |
| 9 | Eli Lilly And Company | 18 | $4.67B |
| 10 | Amerisourcebergen Drug Corp | 497 | $3.23B |
Track this on BesaGov
Get a free weekly email when this changes — new awards, new sub-awards, new opportunities. No login required.
Continue learning
Keep researching
Frequently asked questions
What is contract 36F79724D0115?
Contract 36F79724D0115 is a federal contract awarded to Revance Therapeutics, Inc. by Department Of Veterans Affairs on April 22, 2024 for an undisclosed amount of work classified under PHARMACEUTICAL PREPARATION MANUFACTURING. It has been modified 4 times since the base award.
Who won contract 36F79724D0115?
Revance Therapeutics, Inc. won contract 36F79724D0115 from Department Of Veterans Affairs.
How much is contract 36F79724D0115 worth?
Contract 36F79724D0115 has obligated $0 to date but carries a potential ceiling of $225,000 if fully funded and all options are exercised.